ITVISMA TREATMENT HAS BEEN LICENSED BY THE EMA.

Novartis's new treatment for SMA, Itvisma (onasemnogene abeparvovec-brve), which received FDA (Food and Drug Administration) approval on November 24, 2025, has also been approved by the EMA (European Medicines Agency). This approval is considered a significant development contributing to the expansion of SMA treatment options.

Itvisma aims to increase mobility and independence in SMA patients by helping to slow the progression of the disease.

Click here for detailed information.